Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 2ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310
R.A.Bekker1, Yu.V.Bykov2 1 David Ben-Gurion University in Negev. 8410501, Israel, Be'er Sheva; 2 Stavropol State Medical University of the Ministry of Health of the Russian Federation. 355017, Russian Federation, Stavropol, ul. Mira, d. 310
Список исп. литературыСкрыть список 1. Алиев К.Т. Клиническая эффективность мемантина при спондилогенных болевых синдромах в пояснице и нижних конечностях. Автореф. дис. … канд. мед. наук. ФГБОУ ВО «Первый СПбГМУ им. акад. И.П.Павлова». СПб., 2003. / Aliev K.T. Klinicheskaia effektivnost' memantina pri spondilogennykh bolevykh sindromakh v poiasnitse i nizhnikh konechnostiakh. Avtoref. dis. … kand. med. nauk. FGBOU VO «Pervyi SPbGMU im. akad. I.P.Pavlova». SPb., 2003. [in Russian] 2. Булдакова Н.Ф., Мугутдинова Б.Т., Овчаров В.В. и др. Диагностика и лечение когнитивных нарушений при рассеянном склерозе. Consilium Medicum. 2007; 8 (9): 53–6. / Buldakova N.F., Mugutdinova B.T., Ovcharov V.V. i dr. Diagnostika i lechenie kognitivnykh narushenii pri rasseiannom skleroze. Consilium Medicum. 2007; 8 (9): 53–6. [in Russian] 3. Вахнина Н.В., Парфенов В.А., Никитина Л.Ю. Когнитивные нарушения при инсульте и их лечение мемантином. Клин. геронтология. 2005; 8 (11): 49–52. / Vakhnina N.V., Parfenov V.A., Nikitina L.Iu. Kognitivnye narusheniia pri insul'te i ikh lechenie memantinom. Klin. gerontologiia. 2005; 8 (11): 49–52. [in Russian] 4. Зинкевич В.А., Графова В.Н., Кукушкин М.Л., Киселев А.В. Эффекты акатинола (мемантина) при центрально-спинальном болевом синдроме. Бюл. эксперим. биологии и медицины. 2000; 5: 500–3. / Zinkevich V.A., Grafova V.N., Kukushkin M.L., Kiselev A.V. Effekty akatinola (memantina) pri tsentral'no-spinal'nom bolevom sindrome. Biul. eksperim. biologii i meditsiny. 2000; 5: 500–3. [in Russian] 5. Исакова Е.В., Котов С.В., Чатаева Г.С. Акатинол мемантин при хронической ишемии головного мозга. Альманах клинической медицины. 2005; 8–3: 143–7. / Isakova E.V., Kotov S.V., Chataeva G.S. Akatinol memantin pri khronicheskoi ishemii golovnogo mozga. Al'manakh klinicheskoi meditsiny. 2005; 8–3: 143–7. [in Russian] 6. Котов С.В., Исакова Е.В., Чатаева Г.С., Прохорова Н.В. Акатинол мемантин в лечении больных ишемическим инсультом. Психиатрия и психофармакотерапия. 2005; 06: 343–5. / Kotov S.V., Isakova E.V., Chataeva G.S., Prokhorova N.V. Akatinol memantin v lechenii bol'nykh ishemicheskim insul'tom. Psychiatry and Psychopharmacotherapy. 2005; 06: 343–5. [in Russian] 7. Одинак М.М., Литвиненко И.В., Емелин А.Ю. Открытое сравнительное исследование эффективности мемантина в терапии посттравматических когнитивных расстройств. Неврол. журн. 2005; 6 (10): 32–8. / Odinak M.M., Litvinenko I.V., Emelin A.Iu. Otkrytoe sravnitel'noe issledovanie effektivnosti memantina v terapii posttravmaticheskikh kognitivnykh rasstroistv. Nevrol. zhurn. 2005; 6 (10): 32–8. [in Russian] 8. Соломатин Ю.В., Курбатова В.В., Сердюк И.Е. и др. Опыт применения препарата мемантин у больных с фокальной эпилепсией и когнитивными нарушениями. Эпилепсия и пароксизмальные состояния. 2013; 2 (5): 11–7. / Solomatin Yu.V., Kurbatova V.V., Serdiuk I.E. i dr. Opyt primeneniia preparata memantin u bol'nykh s fokal'noi epilepsiei i kognitivnymi narusheniiami. Epilepsiia i paroksizmal'nye sostoianiia. 2013; 2 (5): 11–7. [in Russian] 9. Ahmad-Sabry MH, Shareghi G. Effects of memantine on pain in patients with complex regional pain syndrome – a retrospective study. Middle East J Anaesthesiol 2015; 23 (1): 51–4. 10. Beister A, Kraus P, Kuhn W et al. The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm 2004; (Suppl.) 68: 117–22. 11. Bigal M, Rapoport A, Sheftell F et al. Memantine in the preventive treatment of refractory migraine. Headache 2008; 48 (9): 1337–42. 12. Blecic S, Rynkowski M, De Witte O et al. Glutamate and malignant gliomas, from epilepsia to biological aggressiveness: therapeutic implications. (Article in French). Bull Cancer. 2013; 100 (9): 829–35. 13. Cankurtaran ES, Ozalp E, Soygur H et al. Clinical experience with risperidone and memantine in the treatment of Huntington's disease. J Natl Med Assoc 2006; 98 (8): 1353–5. 14. Carter RL, Chen Y, Kunkanjanawan T et al. Reversal of cellular phenotypes in neural cells derived from Huntington's disease monkey-induced pluripotent stem cells. Stem Cell Reports 2014; 3 (4): 585–93. 15. Charles A, Flippen C, Romero Reyes M, Brennan KC. Memantine for prevention of migraine: a retrospective study of 60 cases. J Headache Pain 2007; 8 (4): 248–50. 16. Curto M, Lionetto L, Negro A et al. Altered serum levels of kynurenine metabolites in patients affected by cluster headache. J Headache Pain 2015; 17 (1): 27. 17. Dau A, Gladding CM, Sepers MD et al. Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice. Neurobiol Dis 2014; 62: 533–42. 18. De Carvalho M, Pinto S, Costa J et al. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010; 11 (5): 456–60. 19. Dhir A, Chopra K. Memantine delayed N-methyl-D-aspartate – induced convulsions in neonatal rats. Fundam Clin Pharmacol 2015; 29 (1): 72–8. 20. Diederich NJ, McIntyre DJ. Sleep disorders in Parkinson's disease: many causes, few therapeutic options. J Neurol Sci 2012; 314 (1–2): 12–9. 21. Eisenberg E, Kleiser A, Dortort A et al. The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study. Eur J Pain 1998; 2 (4): 321–7. 22. Elbers RG, Verhoef J, van Wegen EE et al. Interventions for fatigue in Parkinson's disease. Cochrane Database Syst Rev 2015; (10): CD010925. 23. Farjam M, Beigi Zarandi FB, Farjadian S et al. Inhibition of NR2B-Containing N-methyl-D-Aspartate Receptors (NMDARs) in Experimental Autoimmune Encephalomyelitis, a Model of Multiple Sclerosis. Iran J Pharm Res 2014; 13 (2): 695–705. 24. Hackworth RJ, Tokarz KA, Fowler IM et al. Profound pain reduction after induction of memantine treatment in two patients with severe phantom limb pain. Anesth Analg 2008; 107 (4): 1377–9. 25. He D, Zhang Y, Dong S et al. Pharmacological treatment for memory disorder in multiple sclerosis. Cochrane Database Syst Rev 2013; 12: CD008876. 26. Hindle JV. The practical management of cognitive impairment and psychosis in the older Parkinson's disease patient. J Neural Transm (Vienna) 2013; 120 (4): 649–53. 27. Hjermind LE, Law I, Jonch A et al. Huntington's disease: effect of memantine on FDG-PET brain metabolism? J Neuropsychiatry Clin Neurosci 2011; 23 (2): 206–10. 28. Huang CY, Wang LC, Wang HK et al. Memantine alleviates brain injury and neurobehavioral deficits after experimental subarachnoid hemorrhage. Mol Neurobiol 2015; 51 (3): 1038–52. 29. Jain KK. Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs 2000; 9 (6): 1397–406. 30. Kafi H, Salamzadeh J, Beladimoghadam N et al. Study of the neuroprotective effects of memantine in patients with mild to moderate ischemic stroke. Iran J Pharm Res 2014; 13 (2): 591–8. 31. Kasatkin DS. Pathogenetic therapy of spasticity. (Article in Russian). Zh Nevrol Psikhiatr Im SS Korsakova 2008; 108 (3): 80–5. 32. Kelestemur T, Yulug B, Caglayan AB et al. Targeting different pathophysiological events after traumatic brain injury in mice: Role of melatonin and memantine. Neurosci Lett 2016; 612: 92–7. 33. Lee ST, Chu K, Jung KH et al. Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement. J Cereb Blood Flow Metab 2006; 26 (4): 536–44. 34. Leroi I, Atkinson R, Overshott R. Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2014; 29 (9): 899–905. 35. Lindelof K, Bendtsen L. Memantine for prophylaxis of chronic tension-type headache – a double-blind, randomized, crossover clinical trial. Cephalalgia 2009; 29 (3): 314–21. 36. López-Valdés HE, Clarkson AN, Ao Y et al. Memantine enhances recovery from stroke. Stroke 2014; 45 (7): 2093–100. 37. Lovera JF, Frohman E, Brown TR et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 2010; 16 (6): 715–23. 38. Mehta LR, McDermott MP, Goodman AD, Schwid SR. A randomized trial of memantine as treatment for spasticity in multiple sclerosis. Mult Scler 2010; 16 (2): 248–51. 39. Milnerwood AJ, Kaufman AM, Sepers MD et al. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice. Neurobiol Dis 2012; 48 (1): 40–51. 40. Moreau C, Delval A, Tiffreau V et al. Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry 2013; 84 (5): 552–5. 41. Morel V, Joly D, Villatte C et al. Memantine before Mastectomy Prevents Post-Surgery Pain: A Randomized, Blinded Clinical Trial in Surgical Patients. PLoS One 2016; 11 (4): e0152741. 42. Mundinger F, Milios E. Experiences with memantine in the treatment of severe spastic and extrapyramidal movement disorders in combination with stereotaxic surgery. (Article in German). Nervenarzt 1985; 56 (2): 106–9. 43. Nikolajsen L, Gottrup H, Kristensen AG, Jensen TS. Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth Analg 2000; 91 (4): 960–6. 44. Noruzzadeh R, Modabbernia A, Aghamollaii V et al. Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double-Blind Placebo-Controlled Study. Headache 2016; 56 (1): 95–103. 45. Olivan-Blázquez B, Herrera-Mercadal P, Puebla-Guedea M et al. Efficacy of memantine in the treatment of fibromyalgia: A double-blind, randomised, controlled trial with 6-month follow-up. Pain 2014; 155 (12): 2517–25. 46. Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord 2007; 13 (7): 453–4. 47. Ondo WG, Shinawi L, Davidson A et al. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism Relat Disord 2011; 17 (3): 156–9. 48. Ozsüer H, Görgülü A, Kiriş T, Cobanoğlu S. The effects of memantine on lipid peroxidation following closed-head trauma in rats. Neurosurg Rev 2005; 28 (2): 143–7. 49. Park BY, Park SH, Kim WM et al. Antinociceptive Effect of Memantine and Morphine on Vincristine-induced Peripheral Neuropathy in Rats. Korean J Pain 2010; 23 (3): 179–85. 50. Peyro Saint Paul L, Creveuil C1, Heinzlef O et al. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. J Neurol Sci 2016; 363: 69–76. 51. Pickering G, Morel V, Joly D et al. Prevention of post-mastectomy neuropathic pain with memantine: study protocol for a randomized controlled trial. Trials 2014; 15: 331. 52. Rohde H. Results of clinical trials of the antispasmodic agent memantine. (Article in German). Fortschr Med 1982; 100 (43): 2023–6. 53. Sang CN, Booher S, Gilron I et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002; 96 (5): 1053–61. 54. Schley M, Topfner S, Wiech K et al. Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine preventsphantom pain in acute traumatic upper limb amputees. Eur J Pain. 2007; 11 (3): 299–308. 55. Sinis N, Birbaumer N, Gustin S et al. Memantine treatment of complex regional pain syndrome: a preliminary report of six cases. Clin J Pain 2007; 23 (3): 237–43. 56. Sinis N, Birbaumer N, Schwarz A et al. Memantine and Complex Regional Pain Syndrome (CRPS): effects of treatment and cortical reorganisation. (Article in German). Handchir Mikrochir Plast Chir 2006; 38 (3): 164–71. 57. Sonkusare SK, Kaul CL, Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope. Pharmacol Res 2005; 51 (1): 1–17. 58. Sulkowski G, Dąbrowska-Bouta B, Salińska E et al. Modulation of glutamate transport and receptor binding by glutamate receptor antagonists in EAE rat brain. PLoS One 2014; 9 (11): e113954. 59. Takano T, Lin JH, Arcuino G et al. Glutamate release promotes growth of malignant gliomas. Nat Med 2001; 7 (9): 1010–5. 60. Varanese S, Howard J, Di Rocco A. NMDA antagonist memantine improves levodopa-induced dyskinesias and on-off phenomena in Parkinson's disease. Mov Disord 2010; 25 (4): 508–10. 61. Vasil'ev DS, Tumanova NL, Lavrent'eva VV et al. The ability of NMDA glutamate receptor blockers to prevent a pentylenetetrazole kindling in mice and morphological changes in the hippocampus. (Article in Russian). Ross Fiziol Zh Im IM Sechenova 2013; 99 (9): 1023–35. 62. Vidal EI, Fukushima FB, Valle AP et al. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia. J Am Geriatr Soc 2013; 61 (1): 170–2. 63. Villoslada P, Arrondo G, Sepulcre J et al. Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009; 72 (19): 1630–3. 64. Wesnes KA, Aarsland D, Ballard C et al. Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2015; 30 (1): 46–54. 65. Wiech K, Kiefer RT, Töpfner S et al. A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth Analg 2004; 98 (2): 408–13.